{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:56:55Z","timestamp":1778914615776,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T00:00:00Z","timestamp":1378339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T00:00:00Z","timestamp":1378339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s10637-013-0011-3","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T04:55:54Z","timestamp":1378270554000},"page":"1499-1504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I\/II study of the AGO Study Group (AGO-OVAR 2.13)"],"prefix":"10.1007","volume":"31","author":[{"given":"Philipp","family":"Harter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Kimmig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kurzeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Elser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,5]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","volume":"121","author":"P Harter","year":"2011","unstructured":"Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, Kommoss S, Heitz F, Traut A, du Bois A (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121:615\u2013619","journal-title":"Gynecol Oncol"},{"issue":"26","key":"11_CR2","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484\u20132496","journal-title":"N Engl J Med"},{"issue":"14","key":"11_CR3","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312\u20133322","journal-title":"J Clin Oncol"},{"issue":"23","key":"11_CR4","first-page":"5536","volume":"55","author":"DK Moscatello","year":"1995","unstructured":"Moscatello DK, Holgado-Madruga M, Godwin AK et al (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55(23):5536\u20135539","journal-title":"Cancer Res"},{"issue":"2","key":"11_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/bjc.1995.339","volume":"72","author":"G Scambia","year":"1995","unstructured":"Scambia G, Benedetti-Panici P, Ferrandina G et al (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72(2):361\u2013366","journal-title":"Br J Cancer"},{"issue":"18","key":"11_CR6","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/jnci\/93.18.1375","volume":"93","author":"O Alper","year":"2001","unstructured":"Alper O, Bergmann-Leitner ES, Bennett TA et al (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93(18):1375\u20131384","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"11_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1046\/j.1525-1438.2001.011002119.x","volume":"11","author":"I Skirnisdottir","year":"2001","unstructured":"Skirnisdottir I, Sorbe B, Seidal T (2001) The growth factor receptors HER-2\/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11(2):119\u2013129","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"11_CR8","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1002\/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO;2-5","volume":"92","author":"Z Chen","year":"2001","unstructured":"Chen Z, Fadiel A, Feng Y et al (2001) Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer 92(12):3068\u20133075","journal-title":"Cancer"},{"issue":"4","key":"11_CR9","first-page":"1546","volume":"9","author":"F Ciardiello","year":"2003","unstructured":"Ciardiello F, Caputo R, Damiano V et al (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9(4):1546\u20131556","journal-title":"Clin Cancer Res"},{"issue":"16","key":"11_CR10","first-page":"4645","volume":"62","author":"SR Wedge","year":"2002","unstructured":"Wedge SR, Ogilvie DJ, Dukes M et al (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62(16):4645\u20134655","journal-title":"Cancer Res"},{"issue":"9","key":"11_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1097\/01243894-200611000-00014","volume":"1","author":"T Tamura","year":"2006","unstructured":"Tamura T, Minami H, Yamada Y et al (2006) A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1(9):1002\u20131009","journal-title":"J Thorac Oncol"},{"issue":"8","key":"11_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","volume":"16","author":"SN Holden","year":"2005","unstructured":"Holden SN, Eckhardt SG, Basser R et al (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16(8):1391\u20131397","journal-title":"Ann Oncol"},{"issue":"8","key":"11_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/JTO.0b013e3181e3a2d1","volume":"5","author":"FH Blackhall","year":"2010","unstructured":"Blackhall FH, O\u2019brien M, Schmid P et al (2010) A phase I study of Vandetanib in combination with vinorelbine\/cisplatin or gemcitabine\/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 5(8):1285\u20131288","journal-title":"J Thorac Oncol"},{"issue":"8","key":"11_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","volume":"29","author":"RH de Boer","year":"2011","unstructured":"de Boer RH, Arrieta \u00d3, Yang CH et al (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29(8):1067\u20131074","journal-title":"J Clin Oncol"},{"issue":"1","key":"11_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000330769","volume":"81","author":"P Saletti","year":"2011","unstructured":"Saletti P, Sessa C, De Dosso S et al (2011) Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology 81(1):50\u201354","journal-title":"Oncology"},{"issue":"4","key":"11_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00280-008-0914-4","volume":"64","author":"MP Saunders","year":"2009","unstructured":"Saunders MP, Wilson R, Peeters M et al (2009) Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. Cancer Chemother Pharmacol 64(4):665\u2013672","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"11_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s10637-011-9656-y","volume":"30","author":"EC Cabebe","year":"2012","unstructured":"Cabebe EC, Fisher GA, Sikic BI (2012) A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs 30(3):1082\u20131087","journal-title":"Invest New Drugs"},{"issue":"5","key":"11_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1200\/JCO.2011.37.7002","volume":"30","author":"TK Choueiri","year":"2012","unstructured":"Choueiri TK, Ross RW, Jacobus S et al (2012) Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30(5):507\u2013512","journal-title":"J Clin Oncol"},{"key":"11_CR19","unstructured":"Thornton K, Kim G, Maher VE, et al. (2012) Vandetanib for the Treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration Drug Approval Summary. Clin Cancer Res. 2012 Jun 4 (Epub ahead of print)"},{"issue":"2","key":"11_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/1078-0432.CCR-09-2308","volume":"16","author":"CM Annunziata","year":"2010","unstructured":"Annunziata CM, Walker AJ, Minasian L et al (2010) Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2. Clin Cancer Res 16(2):664\u2013672","journal-title":"Clin Cancer Res"},{"key":"11_CR21","doi-asserted-by":"crossref","unstructured":"Vergote IB, Joly F, Katsaros D, et al. (2012) Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. J Clin Oncol 30, (suppl; abstr LBA5000)","DOI":"10.1200\/jco.2012.30.15_suppl.lba5000"},{"key":"11_CR22","doi-asserted-by":"crossref","unstructured":"du Bois A, Floquet A, Kim JW, et al. (2013) Randomized, Double-blind, Phase III Trial of Pazopanib vs Placebo in Women Who Have Not Progressed After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Results of an International Intergroup Trial. AGO-OVAR 16: A GCIG Intergroup Study J Clin Oncol 31, (suppl; abstr LBA5503)","DOI":"10.1200\/jco.2013.31.18_suppl.lba5503"},{"key":"11_CR23","doi-asserted-by":"crossref","unstructured":"Coleman RL, Moon J, Soon A, et al. (2012) Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. J Clin Oncol 30, (suppl; abstr 5015)","DOI":"10.1200\/jco.2012.30.15_suppl.5015"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-0011-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0011-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:41:34Z","timestamp":1678509694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-0011-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,5]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-0011-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,5]]},"assertion":[{"value":"24 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}